Hal Wolf announced as new CEO, president of HIMSS

Hal Wolf, previous director with the Chartis Group, has been announced as the new CEO at HIMSS. Wolf replaces Stephen Lieber who held the position for 17 years.

Lieber announced he would be retiring in late 2016. Prior to his years with Chartis, Wolf was the senior vice president and chief operating officer of Kaiser Permanente’s Permanente Federation, where worked in the development of delivery strategies, data management and governance, population care management and the implementation of innovative technologies.

“He sees and creates opportunities, brings people together, and facilitates their success in creating new and better products and services. We are excited that he will be focusing his full energy and efforts to lead HIMSS, as it advances its vision of improving health through information technology and its mission to globally lead endeavors optimizing health engagements and care outcomes through information technology,” said Sebastian Krolop, former HIMSS Board Chair.

This is not the first time Wolf has been associated with HIMSS. He has served as both an advisor to and member of its board and its vice chair for 2016-17..

"Hal Wolf brings to his new role as president and CEO of HIMSS the powerful combination of broad, deep and relevant knowledge, expertise, experience, energy and accomplishments, along with a deep love of and longstanding commitment to HIMSS," said Michael Zaroukian, MD, HIMSS board chair. "His track record of innovation and success spans premier healthcare delivery organizations, digital strategy groups, media companies, global endeavors and more."

“It is a great privilege and honor to be chosen to lead HIMSS, an organization whose purpose is to improve healthcare and care outcomes. Across the globe, healthcare is challenged to harness the power of information and technology, to solve for the unique environments of each health system and to support the personalization of care to the individual. In alliance with the growing membership of HIMSS and the expansive capabilities of our organization, our collective task is to enable innovation across the full healthcare ecosystem,” said Wolf.

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.